Breye Therapeutics ApS
Private limited companyCVR 40279865HørsholmActive
Breye Therapeutics ApS is a private limited company, based in Hørsholm, active in manufacture of pharmaceutical preparations, founded in 2019. Equity was negative at the end of 2026 (−DKK 126.2m). The company made a loss in both 2025 and 2026, most recently DKK 85.6m. 8 other companies in the database are registered at the same address.
Key figures · financial year 2026
What has changed
calculated from recorded figures and datesFinancials: 2026 against 2025
- The loss got smaller: from DKK 89.1m to DKK 85.6m (2025 → 2026).
Management and owners, last 24 months
- New in management: Robert Glenn Blajez (board member, 24/09/2026) and Oskar Lukas Fredrik Ljungström (board member, 24/09/2026).
- Stepped down: Chiara Rossana Maria Liberati (board member, 24/09/2026).
- New owners registered: Novo Holdings A/S (24/09/2026), Sound Bioventures Fund I AB (24/09/2026) and Mission BioCapital VI LP (24/09/2026) (+1).
- No longer registered as owner: BII Holdings A/S (24/09/2026), Sound Bioventures Fund I AB (23/09/2026) and Novo Holdings A/S (23/09/2026) (+2).
Registrations, last 24 months
- 24/09/2026: Share capital changed from 341,672 DKK to 1,026,554 DKK
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2023–2026 · amounts in DKK thousandEquity and net profit
| 2023 | 2024 | 2025 | 2026 | Change | |
|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | – |
| Gross profit | −2,883 | −7,812 | −7,546 | −7,655 | −1.5% |
| Operating profit (EBIT) | −19,836 | −75,372 | −82,639 | −72,319 | +12.5% |
| Profit before tax | −20,777 | −75,646 | −94,640 | −91,075 | +3.8% |
| Net profit | −14,575 | −70,150 | −89,140 | −85,575 | +4% |
| Total assets | 24,815 | 60,682 | 57,048 | 40,585 | −28.9% |
| Equity | 14,526 | 48,485 | −40,638 | −126,213 | −210.6% |
| Liabilities | 10,289 | 12,196 | 97,685 | 166,798 | +70.8% |
| Cash and cash equivalents | 11,385 | 46,499 | 43,061 | 29,206 | −32.2% |
| Average number of employees | 1 | 2 | 3 | 3 | 0% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2023, 2024, 2025, 2026: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2026 figuresNegative equity
Equity was −DKK 126.2m at the end of 2026.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 4 years in a row
Net result has been negative in 2023–2026.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
4 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2026 | 01/04/2025 – 31/03/2026 | 02/10/2026 | The company | PDF not statedXBRL |
| 2025 | 01/04/2024 – 31/03/2025 | 23/09/2025 | The company | PDF not statedXBRL |
| 2024 | 01/04/2023 – 31/03/2024 | 24/09/2024 | The company | PDFXBRL |
| 2023 | 01/04/2022 – 31/03/2023 | 29/09/2023 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
59 companies in the databaseComparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.
Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 69,606of 69,742 Better than 0% | No. 69,933of 69,964 Better than 0% |
| Same industry and fewer than 20 employees37 companies in the comparison | No. 30of 36 Better than 17% | No. 35of 37 Better than 6% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 33,475of 33,588 Better than 0% | No. 33,653of 33,687 Better than 0% |
| All companies of type ApS66,508 companies in the comparison | No. 66,254of 66,379 Better than 0% | No. 66,476of 66,505 Better than 0% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Manufacture of pharmaceutical preparations- Breye Therapeutics ApS−DKK 7.7m
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
- Breye Therapeutics ApS−DKK 85.6m
- Novo Nordisk A/SDKK 102.4bn
- H. Lundbeck A/SDKK 3.2bn
- Breye Therapeutics ApS−DKK 126.2m
- Novo Nordisk A/SDKK 194bn
- H. Lundbeck A/SDKK 24.9bn
- Breye Therapeutics ApS3
- Novo Nordisk A/S27,279
- H. Lundbeck A/S2,261
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Novo Holdings A/S33.33%
- Sound Bioventures Fund I AB15%
- Mission BioCapital VI LP5%
- Sound Bioventures Fund I (D) AB5%
Management
8 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Ulrik Mouritzen | CEO | 13/02/2019 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Jørgen Søberg Petersen | Board member | 04/11/2022 |
| Ulrik Mouritzen | Board member | 04/11/2022 |
| Carl Johan Kördel | Board member | 04/11/2022 |
| Jimmy Arnold V Van Heusden | Chair of the board | 04/11/2022 |
| Gabriela Burian | Board member | 05/12/2022 |
| Robert Glenn Blajez | Board member | 24/09/2026 |
| Oskar Lukas Fredrik Ljungström | Board member | 24/09/2026 |
- Founders
- Visus Holding ApS
Former management (1)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Chiara Rossana Maria Liberati | Board member | 06/06/2023 | 24/09/2026 |
Signing rule: Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse
Address and production units
1 active production unitsAgern Alle 24
2970 Hørsholm
Rudersdal Municipality · Postcode 2970
Other companies at the address (8)
- Altoo ApSWholesale of other machinery and equipment
- Flatirons Emea A/SActivities of non-financial head offices
- Ming Yang Wind Power European R&d Center ApSResearch and experimental development on natural sciences and engineering
- Croxx Med ApSOther professional, scientific and technical activities n.e.c.
- Marigold Investment Management ApSFund management activities
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Breye Therapeutics ApS | Agern Alle 24, 2970 Hørsholm | 2 | 1024431394 |
Purpose
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
The purpose is quoted from the register in Danish.
Changes year by year
57 registered events202614 changesaccounts 1 · capital 1 · management 3 · ownership 9
- AccountsAnnual report for 2026 published
- CapitalShare capital changed from 341,672 DKK to 1,026,554 DKK
- ManagementRobert Glenn Blajez appointed board member
- ManagementOskar Lukas Fredrik Ljungström appointed board member
- ManagementChiara Rossana Maria Liberati stepped down as board member
- OwnershipSound Bioventures Fund I AB registered as owner (15%)
- OwnershipSound Bioventures Fund I (D) AB registered as owner (5%)
- OwnershipMission BioCapital VI LP registered as owner (5%)
- OwnershipNovo Holdings A/S registered as owner (33.33%)
- OwnershipVisus Holding ApS is no longer registered as owner
- OwnershipGolgi NueroSciences S.R.L. is no longer registered as owner
- OwnershipBII Holdings A/S is no longer registered as owner
- OwnershipNovo Holdings A/S is no longer registered as owner
- OwnershipSound Bioventures Fund I AB is no longer registered as owner
20251 changeaccounts 1
- AccountsAnnual report for 2025 published
20248 changesaccounts 1 · capital 2 · ownership 5
- AccountsAnnual report for 2024 published
- CapitalShare capital changed from 325,087 DKK to 341,672 DKK
- OwnershipVisus Holding ApS registered as owner (10%)
- OwnershipGolgi NueroSciences S.R.L. registered as owner (5%)
- OwnershipVisus Holding ApS is no longer registered as owner
- CapitalShare capital changed from 261,065 DKK to 325,087 DKK
- OwnershipNovo Holdings A/S registered as owner (33.33%)
- OwnershipNovo Holdings A/S is no longer registered as owner
202315 changesaccounts 1 · capital 2 · management 1 · ownership 10 · address 1
- AccountsAnnual report for 2023 published
- CapitalShare capital changed from 133,035 DKK to 261,065 DKK
- ManagementChiara Rossana Maria Liberati appointed board member
- OwnershipBII Holdings A/S registered as owner (5%)
- OwnershipVisus Holding ApS registered as owner (15%)
- OwnershipSound Bioventures Fund I AB registered as owner (20%)
- OwnershipBII Holdings A/S is no longer registered as owner
- OwnershipSound Bioventures Fund I AB is no longer registered as owner
- OwnershipVisus Holding ApS is no longer registered as owner
- AddressMoved to Agern Alle 24, 2970 Hørsholm
- CapitalShare capital changed from 125,902 DKK to 133,035 DKK
- OwnershipNovo Holdings A/S registered as owner (33.33%)
- OwnershipBII Holdings A/S registered as owner (10%)
- OwnershipNovo Holdings A/S is no longer registered as owner
- OwnershipBioInnovation Institute Fonden is no longer registered as owner
202213 changesmanagement 5 · name 1 · capital 1 · ownership 6
- ManagementGabriela Burian appointed board member
- NameName changed from Ciana Therapeutics ApS to Breye Therapeutics ApS
- CapitalShare capital changed from 53,500 DKK to 125,902 DKK
- ManagementUlrik Mouritzen appointed board member
- ManagementCarl Johan Kördel appointed board member
- ManagementJimmy Arnold V Van Heusden appointed chair of the board
- ManagementJørgen Søberg Petersen appointed board member
- OwnershipNovo Holdings A/S registered as owner (33.33%)
- OwnershipSound Bioventures Fund I AB registered as owner (5%)
- OwnershipBioInnovation Institute Fonden registered as owner (10%)
- OwnershipVisus Holding ApS registered as owner (33.33%)
- OwnershipBradford A. Young is no longer registered as owner
- OwnershipVisus Holding ApS is no longer registered as owner
20203 changescapital 1 · ownership 1 · name 1
- CapitalShare capital changed from 50,000 DKK to 53,500 DKK
- OwnershipBradford A. Young registered as owner (5%)
- NameName changed from Visus Therapeutics ApS to Ciana Therapeutics ApS
20193 changesfounded 1 · management 1 · ownership 1
- FoundedRegistered as Visus Therapeutics ApS
- ManagementUlrik Mouritzen appointed ceo
- OwnershipVisus Holding ApS registered as owner (90%)
Related companies
Same industry in Rudersdal
- Alk-abelló A/S1,009 employees
- Scanpharm A/S40 employees
- MC2 Therapeutics A/S8 employees
- Synact Pharma ApS7 employees
- Allarity Therapeutics Europe ApS4 employees
Same people in management
- Zealand Pharma A/Svia Jørgen Søberg Petersen
- Hemab ApSvia Jørgen Søberg Petersen
- Acesion Pharma ApSvia Jørgen Søberg Petersen
- Antag Therapeutics ApSvia Jørgen Søberg Petersen
- Allarity Therapeutics Europe ApSvia Jørgen Søberg Petersen
Largest in the industry
- Novo Nordisk A/SDKK 250.3bn
- H. Lundbeck A/SDKK 20.4bn
- Leo Pharma A/SDKK 8.2bn
- Alk-abelló A/SDKK 4.2bn
- Bavarian Nordic A/SDKK 3bn
- Pharmacosmos A/SDKK 1.6bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.